A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Enochian Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 8,700 shares of ENOB stock, worth $40,020. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,700
Holding current value
$40,020
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$4.3 - $4.7 $53,603 - $58,590
12,466 Added 50.32%
37,238 $171,000
Q3 2023

Nov 14, 2023

BUY
$0.0 - $4.46 $0 - $110,483
24,772 New
24,772 $110,000
Q4 2022

Feb 14, 2023

BUY
$1.03 - $2.13 $1 - $2
1 New
1 $0

Others Institutions Holding ENOB

About Enochian Biosciences Inc


  • Ticker ENOB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,950,000
  • Market Cap $244M
  • Description
  • Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...
More about ENOB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.